Table 1.
Patient characteristics
| Total no. of patients | 82 |
|---|---|
| Male/Female | 45/37 |
| Median age (range) | 63 (range 20–89 years) |
| Total no. of each PET study with 18F-FDG and 18F-FBPA | 87 |
| Total no. of target lesions with pathological diagnosis | 88 |
| Malignant tumor (primary/recurrent or metastatic) | 77 (22/55) |
| Oral cavity cancer | 13 |
| Soft tissue sarcoma | 12 |
| Pharyngeal cancer | 10 |
| Salivary gland cancer | 6 |
| External auditory canal cancer | 4 |
| Cancer of the larynx | 3 |
| Skin cancer (mucinous/SCC) | 3 (2/1) |
| Diffuse large B-cell lymphoma | 3 |
| Uterine cancer (endometrial cancer) | 3 |
| Cervical cancer of Uterus (SCC) | 3 |
| Lung cancer (adenocarcinoma) | 2 |
| Mantle cell lymphoma | 2 |
| Esophageal cancer | 2 |
| Olfactory neuroblastoma | 1 |
| Ovarian cancer | 1 |
| Chronic lymphocytic leukemia | 1 |
| Pancreatic cancer | 1 |
| Gallbladder cancer | 1 |
| Bile duct cancer | 1 |
| Maxillary cancer | 1 |
| Breast cancer | 1 |
| Acute myeloid leukemia | 1 |
| Cancer of unknown primary, Cervical lymph node metastasis | 1 |
| Extramammary Paget’s disease | 1 |
| Benign lesion | 11 |
| Inflammatory granulation | 2 |
| Radiation osteomyelitis | 2 |
| Abscess | 2 |
| Inflammatory lymphadenopathy | 1 |
| Tonsillitis | 1 |
| Post-treatment change after chemoradiotherapy | 1 |
| Cholecystitis | 1 |
| Graft versus host disease | 1 |
SCC squamous cell carcinoma